



General shareholders' meeting

Paris, 10 September 2010 at 7.45pm

Conversion of preferred shares

A general meeting and a special meeting of AB Science shareholders were held on 8 September 2010, under the chairmanship of Alain Moussy, CEO of the Company.

The shareholders voted *inter alia* for the conversion of all 432,000 preferred shares « P » into ordinary shares. These new ordinary shares will belong to the same category and will be similar to the shares already traded on NYSE Euronext Paris SA (Compartment B - ISIN code FR 0010557264). The Company has requested the listing of these new ordinary shares for trading on the NYSE Euronext Paris market. This listing should be effective as of 15 September 2010. As a result, the total number of shares accepted for trading on NYSE Euronext Paris SA will be increased from 29,925,850 to 30,357,850.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signalling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases and central nervous system diseases), in both human and veterinary medicines. Thanks to its extensive research and development capabilities, AB Science has its own portfolio of molecules. masitinib, a lead compound, has already been registered in veterinary medicine in Europe and is in the middle of three on-going phases 3 in human medicine in pancreatic cancer, GIST and mastocytosis.

More information on AB Science's website: www.ab-science.com

Citigate
Dewe Rogerson

AB Science - Financial Communication & Press Relations
Agnès Villeret - Tel: +33 (0)1 53 32 78 95 - agnes.villeret@citigate.fr